Results 31 to 40 of about 5,159 (158)

Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia

, 2022
Background: Evolocumab is a fully human monoclonal antibody inhibitor of PCSK9 approved for lowering low-density lipoprotein cholesterol in adults and pediatric patients with familial hypercholesterolemia (FH). The cognitive safety of evolocumab has been
Hovingh, G. Kees, Hamer, Andrew, Mach, François, Raal, Frederick J., Maruff, Paul, Gaudet, Daniel, Gaudet, Isabelle, Pierre, Julie St, Schembri, Adrian, Santos, Raul D., Bergeron, Jean, Ruzza, Andrea, Bridges, Ian, Kastelein, John J. P., Wiegman, Albert   +14 more
core   +2 more sources

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies

Cardiology and Therapy, 2020
Introduction Clinicians, payers, guideline committees, and policymakers support the use of high-intensity statins in patients at high risk for complications of cardiovascular disease (CVD).
Michael J. Koren, Peter H. Jones, Jennifer G. Robinson, David Sullivan, Leslie Cho, Thomas Hucko, J. Antonio G. Lopez, Alex N. Fleishman, Ransi Somaratne, Erik Stroes   +9 more
doaj   +1 more source

Early Addition of Evolocumab to Statin Treatment in Patients with Acute Coronary Syndrome and Multivessel Disease Undergoing Percutaneous Coronary Intervention

Reviews in Cardiovascular Medicine, 2023
Background: Evolocumab has been demonstrated to significantly reduce ischemic cardiovascular events in patients with stable coronary heart disease. However, it is currently unclear whether this benefit extends to patients with acute coronary syndrome ...
Yahao Zhang, Anjian Zhang, Yong Wu, Yanghui Zhang, Weiwei Hu, Penglei Chen, Kui Chen, Jiandong Ding   +7 more
doaj   +1 more source

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolaemia [PDF]

, 2016
BACKGROUND: Evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9, is safe and effective when dosed biweekly (Q2W) or monthly (QM) in patients with heterozygous familial hypercholesterolemia (HeFH) as ...
Raal, Frederick J., STEFANUTTI, Claudia, Kees Hovingh, G., Lira, Armando, Dent, Ricardo, Somaratne, Ransi, Descamps, Olivier, Sullivan, David, Bridges, Ian   +8 more
core   +2 more sources

Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data

BMJ Open, 2022
Objective The FOURIER trial showed a benefit of the PCSK9 inhibitor evolocumab over placebo with respect to cardiovascular outcomes in patients with cardiovascular disease. However, we observed some inconsistencies between the information in the Clinical
Ken Bassett, James Wright, Leire Leache, Luis Carlos Saiz, Juan Erviti, Thomas L Perry, Mohamed Ben-Eltriki, Ciprian Jauca, Marta Gutiérrez-Valencia   +8 more
doaj   +1 more source

Effect of evolocumab on lipoprotein particles

, 2018
The level of low-density lipoprotein cholesterol (LDL-C) reflects the cholesterol carried mainly by low-density lipoprotein particles (LDL-P). LDL-C, however, does not always correlate with LDL-P because of the variable amounts of cholesterol per ...
Toth, Peter P., Dirk J. Blom, Peter P. Toth, Mary Elliott, Monsalvo, Maria Laura, Seth S. Martin, Sattar, Naveed, David Preiss, Davis, Mike, Naveed Sattar, Martin, Seth S., Jones, Steven R., Steven R. Jones, Blom, Dirk J., Maria Laura Monsalvo, Ransi Somaratne, Elliott, Mary, Mike Davis, Somaratne, Ransi, Preiss, David   +19 more
core   +2 more sources

Early effects of PCSK9 inhibitors: evolocumab versus alirocumab [PDF]

Kosin Medical Journal
Background The significance of risk modification in patients with acute coronary syndrome (ACS) is well recognized; however, the optimal timing for adminstering PCSK9 inhibitors remains unclear. Additionally, the lipid-lowering efficacy of evolocumab and
Su-Hyun Bae, Bong-Joon Kim, Soo-Jin Kim, Sung-Il Im, Hyun-Su Kim, Jung-Ho Heo   +5 more
doaj   +1 more source

Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS). [PDF]

, 2019
BACKGROUND While guidelines recommend in-hospital initiation of high-intensity statin therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target levels are frequently not attained. Evolocumab, a rapidly
Deckarm, O., Mach, F., Mach, François, Crljenica, C., Mueller, Christian, Gencer, Baris, Heg, D., Crljenica, Carmela, Matter, C.M., Amini, P., Iglesias, J.F., Cook, Stéphane, Muller, O., Koskinas, K.C., Gencer, B., Windecker, S., Räber, L., Iglesias, Juan F, Heg, Dik, Muller, Olivier, Windecker, Stephan, Häner, Jonas, Mueller, C., Matter, Christian M, Pedrazzini, Giovanni, Amini, Poorya, Cook, S., Koskinas, Konstantinos C, Räber, Lorenz, Häner, J., Pedrazzini, G., Deckarm, Olga   +31 more
core   +1 more source

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

CJC Open, 2022
Background: The 2021 Canadian Cardiovascular Society guidelines recommend proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with atherosclerotic cardiovascular disease whose low-density lipoprotein cholesterol (LDL-C ...
Milan Gupta, MD, G.B. John Mancini, MD, Rajvi J. Wani, PhD, Vineeta Ahooja, MD, Jean Bergeron, MD, MSc, Priya Manjoo, MD, A. Shekhar Pandey, MD, Maureen Reiner, MS, MA, Johnny Beltran, MD, MSc, Thiago Oliveira, MD, Erin S. Mackinnon, PhD   +10 more
doaj   +1 more source

Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the pan-European HEYMANS study.
Vladimír Blaha MUDr, CSc, Roman Margoczy MUDr, Ivo Petrov MD, Arman Postadzhiyan MD, PhD, FESC, FACC, Katarína Rašlová MUDr, CSc, Hana Rosolová MUDr, DrSc, Ian Bridges MSc, Nafeesa N. Dhalwani PhD, Marie Zachlederova PhD, Kausik K. Ray FESC   +9 more
doaj   +1 more source